288 related articles for article (PubMed ID: 12610189)
21. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.
Oosterwijk-Wakka JC; Tiemessen DM; Bleumer I; de Vries IJ; Jongmans W; Adema GJ; Debruyne FM; de Mulder PH; Oosterwijk E; Mulders PF
J Immunother; 2002; 25(6):500-8. PubMed ID: 12439347
[TBL] [Abstract][Full Text] [Related]
22. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
Avigan DE; Vasir B; George DJ; Oh WK; Atkins MB; McDermott DF; Kantoff PW; Figlin RA; Vasconcelles MJ; Xu Y; Kufe D; Bukowski RM
J Immunother; 2007 Oct; 30(7):749-61. PubMed ID: 17893567
[TBL] [Abstract][Full Text] [Related]
24. Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses.
Zhou J; Weng D; Zhou F; Pan K; Song H; Wang Q; Wang H; Wang H; Li Y; Huang L; Zhang H; Huang W; Xia J
Cancer Immunol Immunother; 2009 Oct; 58(10):1587-97. PubMed ID: 19221746
[TBL] [Abstract][Full Text] [Related]
25. Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12.
Ulchaker J; Panuto J; Rayman P; Novick A; Elson P; Tubbs R; Finke JH; Bukowski RM
J Immunother; 1999 Jan; 22(1):71-9. PubMed ID: 9924702
[TBL] [Abstract][Full Text] [Related]
26. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
[TBL] [Abstract][Full Text] [Related]
27. Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody.
Kim JA; Bresler HS; Martin EW; Aldrich W; Heffelfinger M; Triozzi PL
Cancer; 1999 Jul; 86(1):22-30. PubMed ID: 10391559
[TBL] [Abstract][Full Text] [Related]
28. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
Mulders P; Tso CL; Gitlitz B; Kaboo R; Hinkel A; Frand S; Kiertscher S; Roth MD; deKernion J; Figlin R; Belldegrun A
Clin Cancer Res; 1999 Feb; 5(2):445-54. PubMed ID: 10037196
[TBL] [Abstract][Full Text] [Related]
29. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.
Figlin RA; Pierce WC; Kaboo R; Tso CL; Moldawer N; Gitlitz B; deKernion J; Belldegrun A
J Urol; 1997 Sep; 158(3 Pt 1):740-5. PubMed ID: 9258071
[TBL] [Abstract][Full Text] [Related]
30. Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes).
Gratama JW; Schmitz PI; Goey SH; Lamers CH; Stoter G; Bolhuis RL
Int J Cancer; 1996 Jan; 65(2):152-60. PubMed ID: 8567110
[TBL] [Abstract][Full Text] [Related]
31. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
[TBL] [Abstract][Full Text] [Related]
32. Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.
Markel G; Cohen-Sinai T; Besser MJ; Oved K; Itzhaki O; Seidman R; Fridman E; Treves AJ; Keisari Y; Dotan Z; Ramon J; Schachter J
Anticancer Res; 2009 Jan; 29(1):145-54. PubMed ID: 19331144
[TBL] [Abstract][Full Text] [Related]
33. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.
Thompson JA; Shulman KL; Benyunes MC; Lindgren CG; Collins C; Lange PH; Bush WH; Benz LA; Fefer A
J Clin Oncol; 1992 Jun; 10(6):960-8. PubMed ID: 1588376
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer.
Curti BD; Ochoa AC; Powers GC; Kopp WC; Alvord WG; Janik JE; Gause BL; Dunn B; Kopreski MS; Fenton R; Zea A; Dansky-Ullmann C; Strobl S; Harvey L; Nelson E; Sznol M; Longo DL
J Clin Oncol; 1998 Aug; 16(8):2752-60. PubMed ID: 9704728
[TBL] [Abstract][Full Text] [Related]
35. Prolonged culture of vaccine-primed lymphocytes results in decreased antitumor killing and change in cytokine secretion.
Sussman JJ; Parihar R; Winstead K; Finkelman FD
Cancer Res; 2004 Dec; 64(24):9124-30. PubMed ID: 15604282
[TBL] [Abstract][Full Text] [Related]
36. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.
Sloan AE; Dansey R; Zamorano L; Barger G; Hamm C; Diaz F; Baynes R; Wood G
Neurosurg Focus; 2000 Dec; 9(6):e9. PubMed ID: 16817692
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings.
Tani K; Azuma M; Nakazaki Y; Oyaizu N; Hase H; Ohata J; Takahashi K; OiwaMonna M; Hanazawa K; Wakumoto Y; Kawai K; Noguchi M; Soda Y; Kunisaki R; Watari K; Takahashi S; Machida U; Satoh N; Tojo A; Maekawa T; Eriguchi M; Tomikawa S; Tahara H; Inoue Y; Yoshikawa H; Yamada Y; Iwamoto A; Hamada H; Yamashita N; Okumura K; Kakizoe T; Akaza H; Fujime M; Clift S; Ando D; Mulligan R; Asano S
Mol Ther; 2004 Oct; 10(4):799-816. PubMed ID: 15451464
[TBL] [Abstract][Full Text] [Related]
38. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
Belldegrun A; Muul LM; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):206-14. PubMed ID: 3257161
[TBL] [Abstract][Full Text] [Related]
39. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK
Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
[TBL] [Abstract][Full Text] [Related]
40. Adoptive cellular therapy.
Hoffman DM; Gitlitz BJ; Belldegrun A; Figlin RA
Semin Oncol; 2000 Apr; 27(2):221-33. PubMed ID: 10768601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
